-- The Federal Trade Commission has opened an investigation into Teva

Pharmaceutical Industries over its patent practices, the Washington Post

reported on Monday.

-- The probe focuses on the Israeli company's refusal to withdraw patents for

asthma inhalers and treatments for chronic obstructive pulmonary

disease from a federal registry called the Orange Book, according to the Post.

-- The FTC claims Teva made small modifications to keep the patents in the registry

and stifle competition, the Post reported.

-- Teva spokesperson Kelley Dougherty told The Wall Street Journal that the

company's patents are properly listed and that Teva "continues to stand

behind the company's intellectual property."


Full article at https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/


Write to Victor Swezey at victor.swezey@wsj.com


(END) Dow Jones Newswires

07-01-24 1249ET